EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: Cross-Database Consistency in FAERS and JADER

Velizar Shivarov

Hemato · 04.11.2026 · 7 (4) · 41

DOI: 10.3390/hemato7040041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, online erschienen am 04.11.2026. Verfasst von Velizar Shivarov. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian National Science Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are uncommon hematologic immune-related adverse events of immune checkpoint inhibitors (ICIs). We evaluated whether strict reporting signals were consistent across two national spontaneous-reporting systems and whether this consistency persisted after reviewer-requested harmonization analyses.

Methods

We performed a cross-database disproportionality study using cumulative FAERS data through 2025 Q3 and JADER 202608. MedDRA 29.0 preferred-term phenotype definitions and analytic rules were defined before final analysis. Primary analyses used primary/secondary-suspect ICI reports in FAERS and suspected-drug reports in JADER, with oncology-restricted, role-harmonized, common-calendar, interaction, and time-to-onset sensitivity analyses.

Results

FAERS contained 207,459 ICI-exposed reports, including 338 AIHA reports (ROR 8.13, 95% CI 7.26–9.09) and 602 ITP reports (ROR 6.38, 95% CI 5.87–6.93). JADER contained 86,270 ICI-exposed reports, including 128 AIHA reports (ROR 4.27, 95% CI 3.48–5.24) and 410 ITP reports (ROR 3.56, 95% CI 3.18–3.98). Among 20 adequately supported shared comparisons, all were directionally concordant and 19 were positive in both databases. Role-harmonized analysis yielded 18/18 positive comparisons and a common 2025 Q3 cutoff yielded 19/19. Exact-day time to onset was available for 43.8% of JADER AIHA and 51.0% of ITP reports and was sensitive to drug-event interval selection, particularly for AIHA.

Conclusions

Strict ICI-associated AIHA and ITP definitions show robust cross-database directional consistency. These data quantify reporting disproportionality, rather than incidence or clinical risk; cancer-context and temporal findings remain exploratory.

Förderung

  • Bulgarian National Science Fund

Zitieren

APA

Shivarov, V. (2026). Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: Cross-Database Consistency in FAERS and JADER. Hemato, 7(4), 41. https://doi.org/10.3390/hemato7040041

Vancouver

Shivarov V. Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: Cross-Database Consistency in FAERS and JADER. Hemato. 2026;7(4):41. doi:10.3390/hemato7040041

BibTeX
@article{Shivarov2026,
  author = {Shivarov, Velizar},
  title = {Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia and Immune Thrombocytopenia: Cross-Database Consistency in FAERS and JADER},
  journal = {Hemato},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {41},
  doi = {10.3390/hemato7040041}
}
Kostenlos starten →